Phase 2 Sickle Cell Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For the Healthy Volunteer part of the trial (Part 1):
- Men and women who cannot become pregnant, aged between 18 and 55 years old
- People who are in good general health, as confirmed by the study doctor through a check-up, health history review, and basic tests
- People who weigh at least 50 kg (about 110 lbs) and have a body mass index (BMI) between 18.0 and 32.0
For the Sickle Cell Disease part of the trial (Part 2):
- Men and women who have been diagnosed with sickle cell disease
Who may not be able to join:
For the Healthy Volunteer part (Part 1):
- People whose heart's electrical activity shows a certain abnormal reading on a heart tracing test (confirm with trial site)
- People with a history of irregular heartbeat or other heart rhythm problems
- People who have had a significant illness that has not fully cleared up within the two weeks before starting the trial
- Women who are able to become pregnant
For the Sickle Cell Disease part (Part 2):
- People who are currently taking a medication called hydroxyurea or hydroxycarbamide
- People whose heart's electrical activity shows a certain abnormal reading on a heart tracing test (confirm with trial site)
- People with a history of irregular heartbeat or other heart rhythm problems
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-888-669-6682
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part 1A, Part 1B, Part 1C: Incidence of AEs and SAEs; Part 1A, Part 1B , Part 1C: Dose discontinued due to AE; Part 2A, Part 2B: Incidence of AEs and SAEs; Part 2A, Part 2B: Dose interruptions and reductions; Part 2A, Part 2B: Dose intensity; Part 2B: Fetal hemoglobin (HbF)%
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.